Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
View Scopus Profile
Ron Ram
Professor
Clinical (Full) Professor
,
Faculty of Medicine
,
Hematology
2004
2025
Research activity per year
Overview
Fingerprint
Network
Research output
(131)
Similar Profiles
(12)
Fingerprint
Dive into the research topics where Ron Ram is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
41%
Overall Survival
40%
Meta-analysis
36%
Acute Myeloid Leukemia
34%
Systematic Meta-analysis
33%
Relapsed or Refractory
32%
Diffuse Large B-cell Lymphoma (DLBCL)
29%
Confidence Interval
27%
Chimeric Antigen Receptor T Cells (CAR-T)
25%
Hematopoietic Cell Transplantation
25%
Chimeric Antigen Receptor T-cell Therapy
20%
Single Center
19%
Venetoclax
17%
Israel
17%
Multiple Myeloma
16%
Acute Lymphoblastic Leukemia
16%
Oncology Patients
15%
Relative Risk
14%
Transplantation
14%
Acute Leukemia
14%
Cell Therapy
14%
Non-relapse Mortality
13%
Chronic Myeloid Leukemia
13%
Marrow Transplantation
13%
Retrospective multicenter Study
12%
Hazard Ratio
12%
Elderly Patients
12%
European Society
12%
Relapsed or Refractory Acute Myeloid Leukemia
12%
Progression-free Survival
12%
Hematopoietic Stem Cell Transplantation
11%
Refractory Diffuse Large B-cell Lymphoma
11%
Adult Patients
11%
Hematological Malignancies
11%
Tyrosine Kinase Inhibitor
11%
Risk Factors
11%
BNT162b2 Vaccine
10%
First Complete Remission
10%
Novel Agents
10%
Leukemia Patients
10%
Complete Response
10%
Chemotherapy
10%
Rituximab
9%
Randomized Trial
9%
Complete Remission
9%
High Risk
9%
Historical Prospective
9%
Methotrexate
9%
FLT3 mutation
9%
Medicine and Dentistry
Hematopoietic Cell
76%
Cell Transplantation
70%
Overall Survival
38%
Acute Myeloid Leukemia
36%
Diffuse Large B-Cell Lymphoma
34%
Diseases
32%
Infection
23%
Acute Lymphoblastic Leukemia
18%
Venetoclax
17%
Meta-Analysis
17%
Graft Versus Host Reaction
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Progression Free Survival
15%
Multiple Myeloma
15%
Chimeric Antigen Receptor T-Cell
14%
Cohort Analysis
13%
Systematic Review
13%
Cell Therapy
12%
Hematologic Malignancy
11%
Drug Megadose
11%
Acute Leukemia
10%
Febrile Neutropenia
10%
Elderly Patient
10%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Retrospective Study
9%
Immunosuppressive Treatment
9%
Rituximab
9%
Methotrexate
9%
Chronic Graft Versus Host Disease
8%
Clinical Trial
8%
Hematopoietic Stem Cell Transplantation
8%
Non-Hodgkin Lymphoma
8%
Non-Relapse Mortality
8%
Randomized Controlled Trial
8%
Hazard Ratio
8%
Neutropenia
8%
Acute Graft Versus Host Disease
8%
Cord Blood
7%
Cytarabine
7%
Infusion
7%
Arm
7%
Platelet
7%
Induction Chemotherapy
7%
Salvage Therapy
7%
Bloodstream Infection
6%
Lymphoproliferative Disease
6%
Adverse Event
6%
Prospective Study
6%
Case-Control Study
6%
Positron Emission Tomography-Computed Tomography
6%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
35%
Acute Myeloid Leukemia
31%
Remission
26%
Infection
25%
Diseases
23%
Graft Versus Host Reaction
21%
Chimeric Antigen Receptor
19%
Multiple Myeloma
18%
Chemotherapy
16%
Diffuse Large B Cell Lymphoma
15%
Methotrexate
14%
Venetoclax
14%
Randomized Controlled Trial
13%
Hematologic Malignancy
12%
Protein Tyrosine Kinase Inhibitor
12%
Progression Free Survival
11%
Neutropenia
11%
Acute Leukemia
11%
Febrile Neutropenia
10%
Chronic Myeloid Leukemia
10%
Adverse Event
10%
Rituximab
10%
Lymphoproliferative Disease
9%
Gilteritinib
8%
Imatinib
8%
Retrospective Study
7%
Monotherapy
7%
Chronic Graft Versus Host Disease
7%
Clinical Trial
7%
Bloodstream Infection
6%
All Cause Mortality
6%
Telomerase
6%
Cytarabine
6%
Myelodysplastic Syndrome
6%
Prospective Study
6%
Malignant Neoplasm
6%
Polyethylene Terephthalate
6%
Ciclosporin
6%
Acute Lymphoblastic Leukemia
6%
Aplastic Anemia
5%
Midostaurin
5%
Observational Study
5%
Fluorodeoxyglucose F 18
5%
Azacitidine
5%
Mycophenolate Mofetil
5%
Placebo
5%
C Reactive Protein
5%
Mucosa Inflammation
5%
